Cargando…

How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings

Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto‐cerebellar and meso‐cortico‐limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarri, Xavier, Afzali, Mohammad H., Lavoie, Jacob, Sinha, Rajita, Stein, Dan J., Momenan, Reza, Veltman, Dick J, Korucuoglu, Ozlem, Sjoerds, Zsuzsika, van Holst, Ruth J., Hester, Rob, Orr, Catherine, Cousijn, Janna, Yucel, Murat, Lorenzetti, Valentina, Wiers, Reinout, Jahanshad, Neda, Glahn, David C., Thompson, Paul M., Mackey, Scott, Conrod, Patricia J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675406/
https://www.ncbi.nlm.nih.gov/pubmed/32643841
http://dx.doi.org/10.1002/hbm.25114
_version_ 1784615864827379712
author Navarri, Xavier
Afzali, Mohammad H.
Lavoie, Jacob
Sinha, Rajita
Stein, Dan J.
Momenan, Reza
Veltman, Dick J
Korucuoglu, Ozlem
Sjoerds, Zsuzsika
van Holst, Ruth J.
Hester, Rob
Orr, Catherine
Cousijn, Janna
Yucel, Murat
Lorenzetti, Valentina
Wiers, Reinout
Jahanshad, Neda
Glahn, David C.
Thompson, Paul M.
Mackey, Scott
Conrod, Patricia J.
author_facet Navarri, Xavier
Afzali, Mohammad H.
Lavoie, Jacob
Sinha, Rajita
Stein, Dan J.
Momenan, Reza
Veltman, Dick J
Korucuoglu, Ozlem
Sjoerds, Zsuzsika
van Holst, Ruth J.
Hester, Rob
Orr, Catherine
Cousijn, Janna
Yucel, Murat
Lorenzetti, Valentina
Wiers, Reinout
Jahanshad, Neda
Glahn, David C.
Thompson, Paul M.
Mackey, Scott
Conrod, Patricia J.
author_sort Navarri, Xavier
collection PubMed
description Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto‐cerebellar and meso‐cortico‐limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been few large‐scale investigations to compare such findings. The current study uses the Enhancing Neuroimaging Genetics through Meta‐Analysis (ENIGMA) consortium method of standardising structural brain measures to quantify case–control differences and to compare brain‐correlates of substance use disorders with those published in relation to other psychiatric disorders. Using the ENIGMA protocols, we report effect sizes derived from a meta‐analysis of alcohol (seven studies, N = 798, 54% are cases) and cannabis (seven studies, N = 447, 45% are cases) dependent cases and age‐ and sex‐matched controls. We conduct linear analyses using harmonised methods to process and parcellate brain data identical to those reported in the literature for ENIGMA case–control studies of major depression disorder (MDD), schizophrenia (SCZ) and bipolar disorder so that effect sizes are optimally comparable across disorders. R elationships between substance use disorder diagnosis and subcortical grey matter volumes and cortical thickness were assessed with intracranial volume, age and sex as co‐variates . After correcting for multiple comparisons, AUD case–control meta‐analysis of subcortical regions indicated significant differences in the thalamus, hippocampus, amygdala and accumbens, with effect sizes (0.23) generally equivalent to, or larger than |0.23| those previously reported for other psychiatric disorders (except for the pallidum and putamen). On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri. Meta‐analysis of CUD case–control studies indicated reliable reductions in amygdala, accumbens and hippocampus volumes, with the former effect size comparable to, and the latter effect size around half of that reported for alcohol and SCZ. CUD was associated with lower cortical thickness in the frontal regions, particularly the medial orbitofrontal region, but this effect was not significant after correcting for multiple testing. This study allowed for an unbiased cross‐disorder comparison of brain correlates of substance use disorders and showed alcohol‐related brain anomalies equivalent in effect size to that found in SCZ in several subcortical and cortical regions and significantly greater alterations than those found in MDD in several subcortical and cortical regions. Although modest, CUD results overlapped with findings reported for AUD and other psychiatric conditions, but appear to be most robustly related to reduce thickness of the medial orbitofrontal cortex.
format Online
Article
Text
id pubmed-8675406
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-86754062021-12-27 How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings Navarri, Xavier Afzali, Mohammad H. Lavoie, Jacob Sinha, Rajita Stein, Dan J. Momenan, Reza Veltman, Dick J Korucuoglu, Ozlem Sjoerds, Zsuzsika van Holst, Ruth J. Hester, Rob Orr, Catherine Cousijn, Janna Yucel, Murat Lorenzetti, Valentina Wiers, Reinout Jahanshad, Neda Glahn, David C. Thompson, Paul M. Mackey, Scott Conrod, Patricia J. Hum Brain Mapp Research Articles Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto‐cerebellar and meso‐cortico‐limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been few large‐scale investigations to compare such findings. The current study uses the Enhancing Neuroimaging Genetics through Meta‐Analysis (ENIGMA) consortium method of standardising structural brain measures to quantify case–control differences and to compare brain‐correlates of substance use disorders with those published in relation to other psychiatric disorders. Using the ENIGMA protocols, we report effect sizes derived from a meta‐analysis of alcohol (seven studies, N = 798, 54% are cases) and cannabis (seven studies, N = 447, 45% are cases) dependent cases and age‐ and sex‐matched controls. We conduct linear analyses using harmonised methods to process and parcellate brain data identical to those reported in the literature for ENIGMA case–control studies of major depression disorder (MDD), schizophrenia (SCZ) and bipolar disorder so that effect sizes are optimally comparable across disorders. R elationships between substance use disorder diagnosis and subcortical grey matter volumes and cortical thickness were assessed with intracranial volume, age and sex as co‐variates . After correcting for multiple comparisons, AUD case–control meta‐analysis of subcortical regions indicated significant differences in the thalamus, hippocampus, amygdala and accumbens, with effect sizes (0.23) generally equivalent to, or larger than |0.23| those previously reported for other psychiatric disorders (except for the pallidum and putamen). On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri. Meta‐analysis of CUD case–control studies indicated reliable reductions in amygdala, accumbens and hippocampus volumes, with the former effect size comparable to, and the latter effect size around half of that reported for alcohol and SCZ. CUD was associated with lower cortical thickness in the frontal regions, particularly the medial orbitofrontal region, but this effect was not significant after correcting for multiple testing. This study allowed for an unbiased cross‐disorder comparison of brain correlates of substance use disorders and showed alcohol‐related brain anomalies equivalent in effect size to that found in SCZ in several subcortical and cortical regions and significantly greater alterations than those found in MDD in several subcortical and cortical regions. Although modest, CUD results overlapped with findings reported for AUD and other psychiatric conditions, but appear to be most robustly related to reduce thickness of the medial orbitofrontal cortex. John Wiley & Sons, Inc. 2020-07-09 /pmc/articles/PMC8675406/ /pubmed/32643841 http://dx.doi.org/10.1002/hbm.25114 Text en © 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Navarri, Xavier
Afzali, Mohammad H.
Lavoie, Jacob
Sinha, Rajita
Stein, Dan J.
Momenan, Reza
Veltman, Dick J
Korucuoglu, Ozlem
Sjoerds, Zsuzsika
van Holst, Ruth J.
Hester, Rob
Orr, Catherine
Cousijn, Janna
Yucel, Murat
Lorenzetti, Valentina
Wiers, Reinout
Jahanshad, Neda
Glahn, David C.
Thompson, Paul M.
Mackey, Scott
Conrod, Patricia J.
How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
title How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
title_full How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
title_fullStr How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
title_full_unstemmed How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
title_short How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
title_sort how do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? a cross‐disorder meta‐analytic comparison using the enigma consortium findings
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675406/
https://www.ncbi.nlm.nih.gov/pubmed/32643841
http://dx.doi.org/10.1002/hbm.25114
work_keys_str_mv AT navarrixavier howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT afzalimohammadh howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT lavoiejacob howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT sinharajita howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT steindanj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT momenanreza howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT veltmandickj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT korucuogluozlem howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT sjoerdszsuzsika howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT vanholstruthj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT hesterrob howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT orrcatherine howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT cousijnjanna howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT yucelmurat howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT lorenzettivalentina howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT wiersreinout howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT jahanshadneda howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT glahndavidc howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT thompsonpaulm howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT mackeyscott howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings
AT conrodpatriciaj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings